Lasercoagulation or Anti-VEGF: What Is the Better Treatment?



This chapter compares laser coagulation with anti-VEGF treatment and shows in detail the advantages and disadvantages of each treatment method.


Anti-VEGF Laser coagulation Comparison 


  1. 1.
    Feng J, Qian J, Jiang Y, Zhao M, Liang J, Yin H, Chen Y, Yu W, Li X. Efficacy of primary intravitreal ranibizumab for retinopathy of prematurity in China. Ophthalmology. 2017;124(3):408–9.CrossRefGoogle Scholar
  2. 2.
    Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza W, Jendritza B, Jonas JB. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol. 2013;1555(6):1119–24.CrossRefGoogle Scholar
  3. 3.
    Holmström G, Hellström A, Jakobsson P, Lundgren P, Tornqvist K, Wallin A. Five years of treatment for retinopathy of prematurity in Sweden: results from SWEDROP, a national quality register. Br J Ophthalmol. 2016;100(12):1656–61.Google Scholar
  4. 4.
    Hu J, Blair MP, Shapiro MJ, Lichetnstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130(8):1000–6.CrossRefGoogle Scholar
  5. 5.
    Kennedy KA, Mintz-Hittner HA, BEAT-ROP Cooperative Group. Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. J AAPOS. 2018;22(1):61–65.e1.CrossRefGoogle Scholar
  6. 6.
    Lepore D, Quinn GE, Molle F, Orazi L, Baldascino A, Ji MH, Sammartino M, Sbaraglia F, Ricci D, Mercuri E. Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology. 2018;125(2):218–26.CrossRefGoogle Scholar
  7. 7.
    Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603–15.CrossRefGoogle Scholar
  8. 8.
    Mintz-Hittner HA, Geloneck MM, Chuang AZ. Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology. 2016;123(9):1845–55.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.OphthalmologyUniversity of Uppsala OphthalmologyUppsalaSweden
  2. 2.Department of OphthalmologySamsung Medical Center, Sungkyunkwan UniversitySeoulSouth Korea

Personalised recommendations